Clinical Trials Directory

Trials / Completed

CompletedNCT00284271

Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
65 (actual)
Sponsor
University of Cologne · Academic / Other
Sex
All
Age
61 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This study is designed to test (1) feasibility and efficiancy of new BACOPP regimen and (2) toxicity, overall response and FFTF.

Conditions

Interventions

TypeNameDescription
DRUGCyclophosphamide
DRUGAdramycin
DRUGProcarbacine
DRUGPrednisone
DRUGVincristine
DRUGBleomycin
DRUGErythropoietin beta

Timeline

Start date
2004-01-01
Primary completion
2005-12-01
First posted
2006-01-31
Last updated
2011-07-29

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT00284271. Inclusion in this directory is not an endorsement.

Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma (NCT00284271) · Clinical Trials Directory